论文部分内容阅读
Cancer is a disease of dysproliferating cells, suffering from extensive genomic and epigenomic defects and exhibiting excessive in vivo heterogeneity.Among the epigenetic entities, DNA methylation is the best characterized epigenetic mechanisms, aberrantion of which underlies the cancerous state-specific gene expression and therefore the abnormal phenotype of cancer cells.Aberrant DNA methylation is regared as the most promising molecular targets for better diagnostics and therapeutics in cancer management.Chemo-resistance prevents curative chemotherapy of cancer and has been intensively studied in recent years.From a comprehensive integrative multi-omic analysis of a panel of the chemo-sensitive versus resistant cell lines, a number of gene set (pathways) having a role in this process have been identified.The gene-centered (pathway centered) mechanistic and clinical studies are followed.In this talk, I will present the recent advance in effort target to a DNA methylation regulated miR (miR193a) in chemo-resistance of bladder cancer.Its DNA methylation status in urine sediments as the diagnostic biomarkers will be also discussed.